關於 lapatinesg ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Lapatinib: Uses, Interactions, Mechanism of Action - DrugBank

Lapatinib is an antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-positive breast cancer in patients ...

#12. Tykerb (lapatinib) dosing, indications, interactions, adverse ...

Medscape - Breast cancer dosing for Tykerb (lapatinib), frequency-based adverse effects, comprehensive interactions, contraindications, ...

#13. Lapatinib (Oral Route) Proper Use - Mayo Clinic

Dosing · Adults—1250 milligrams (mg) or 5 tablets taken together as a single dose once a day for 21 days. Your doctor may tell you to repeat the ...

#14. Tyverb | European Medicines Agency - European Union

The active substance in Tyverb, lapatinib, belongs to a group of medicines called protein kinase inhibitors. These medicines work by blocking enzymes known as ...

#15. Lapatinib (GW-572016) - EGFR inhibitor - Selleck Chemicals

Lapatinib is a potent purified EGFR and ErbB-2 inhibitor with IC50 of 10.2 and 9.8 nM, respectively. Find all the information about Lapatinib for cell ...

#16. Lapatinib - 台北慈濟醫院

Lapatinib. ◇商品名：. Tykerb 泰嘉錠250 mg/tab. ◇醫生為何開此藥給我. 醫生為何開此藥給我. 醫生為何開此藥給我？ 此藥常與capecitabine 合併使用，用於治.

#17. Lapatinib (GW572016) | EGFR/HER2 Inhibitor

Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, ...

#18. Lapatinib 【O8069】Tykerb® 250mg/Tab ATC Code

Lapatinib. 【O8069】Tykerb® 250mg/Tab. ATC Code：L01EH01. 中文名： 泰嘉錠250 毫克膜衣錠«Novartis». 適應症： 1.在和capecitabine 併用的情況下，TYKERB 適用於 ...

#19. Lapatinib - an overview | ScienceDirect Topics

Lapatinib is a reversible and specific tyrosine kinase receptor inhibitor of both ErbB1 and ErbB2. It is one of several molecularly targeted therapies that ...

#20. Lapatinib: MedlinePlus Drug Information

Lapatinib : learn about side effects, dosage, special precautions, and more on MedlinePlus.

#21. Lapatinib|EGFR/HER2 inhibitor,potent,selective ... - APExBIO

Lapatinib (also known as GW572016), a member of the 4-anilinoquinazoline class of kinase inhibitors, is a potent, reversible and selective small-molecule ...

#22. Lapatinib 231277-92-2 - Sigma-Aldrich

General description. Lapatinib is a tyrosine kinase inhibitor, targeting both the epidermal growth factor receptors, ErbB1 and ErbB-2. In combination with ...

#23. 抗癌新藥- Tykerb (Lapatinib) - 中華民國藥師公會全國聯合會

從這個臨床. 試驗可得知對於HER-2 (+)的局部晚期或. 轉移性乳癌病人來說,lapatinib 與 capecitabine的合併使用優於capecitabine. 單獨使用4。 除了與capecitabine合併使用 ...

#24. Lapatinib Ditosylate - NCI

This page contains brief information about lapatinib ditosylate and a collection of links to more information about the use of this drug, ...

#25. TYKERB® (lapatinib) tablets, for oral use - Accessdata.fda.gov

TYKERB® (lapatinib) tablets, for oral use. Initial U.S. Approval: 2007. WARNING: HEPATOTOXICITY. See full prescribing information for complete boxed warning ...

#26. DRUG NAME: Lapatinib - BC Cancer

Lapatinib is an orally active small molecule tyrosine kinase inhibitor. It is a potent, reversible, and selective inhibitor.

#27. Lapatinib plus Capecitabine for HER2-Positive Advanced ...

Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal ...

#28. Lapatinib | Cell Signaling Technology

Lapatinib is a dual inhibitor of EGFR and HER2 tyrosine kinases (1-4). Researchers have shown that lapatinib inhibits purified EGFR and HER2 tyrosine kinase ...

#29. Lapatinib - Memorial Sloan Kettering Cancer Center

Lapatinib · It is used to treat breast cancer. · Tell all of your health care providers that you take this drug.

#30. Lapatinib and lapatinib plus trastuzumab therapy versus ...

Lapatinib (L) is a tyrosine kinase inhibitor (TKI) that exerts its anti-tumor effects by competing with intracellular ATP to block the HER2 ...

#31. Chemotherapy and Lapatinib or Trastuzumab in Treating ...

Lapatinib is a new drug. Like trastuzumab, it also works by specifically "targeting" the HER2/neu receptor, but it does so in a different way.

#32. Lapatinib (Tykerb, GW572016) Reverses Multidrug ...

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member ...

#33. Lapatinib - Chemotherapy Drugs - Chemocare

Drug type: Lapatinib is a targeted therapy. Lapatinib is classified as a signal transduction inhibitor - tyrosine kinase inhibitor, inhibitor of EGFR and HER2.

#34. Lapatinib Oral: Uses, Side Effects, Interactions ... - WebMD

It works by slowing or stopping the growth of cancer cells. How to use Lapatinib 250 Mg Tablet Antineoplastic - Protein-Tyrosine Kinase Inhibitors. Read the ...

#35. Lapatinib (Tykerb) for Metastatic Breast Cancer Treatment

Lapatinib combined with chemotherapy, hormone therapy or trastuzumab may increase progression-free survival (meaning it may give people more time before the ...

#36. LAPATINIB | Oncohealth Institute

Lapatinib is a drug used primarily to treat women with advanced breast cancer. It can also be used to treat other types of cancer as part of a research ...

#37. Adjuvant Therapy for Breast Cancer - 第 208 頁 - Google 圖書結果

Ongoing Lapatinib Trials for Early Stage HER2 Overexpressing Breast Cancer The data reviewed above suggests that lapatinib may be an important addition to ...

#38. Lapatinib (Tykerb®) | OncoLink

Lapatinib is a tyrosine kinase inhibitor. A kinase is an enzyme that promotes cell growth. There are many types of kinases, which control ...

#39. Lapatinib (拉帕替尼) - 癌症資訊網

拉帕替尼(Lapatinib)能結合上皮生長因子受體(epidermal growth factor receptor；EGFR)及人類表皮生長因子受體-2(human epidermal growth factor receptor ...

#40. Lapatinib (Tykerb): Uses & Side Effects | Cleveland Clinic

Lapatinib treats breast cancer by slowing down the growth of cancer cells. Breast cancer happens when cells in your breast grow and divide in an ...

#41. Lapatinib monotherapy in patients with HER2-overexpressing ...

Lapatinib is an orally bioavailable reversible potent inhibitor of both EGFR and HER2 and induces growth arrest or tumour-cell apoptosis in EGFR ...

#42. Lapatinib Uses, Side Effects & Warnings - Drugs.com

Lapatinib is used to treat advanced hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines.

#43. Lapatinib, a HER2 tyrosine kinase inhibitor, induces ... - Nature

Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified ...

#44. 36-Breast metastatic capecitabine and laPAtinib - eviQ

Breast metastatic capecitabine and laPAtinib ... laPAtinib, 1,250 mg ONCE a day, PO, 1 to 21 ... Lapatinib is available as 250 mg tablets.

#45. Impact of lapatinib plus trastuzumab versus single-agent ...

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Y.

#46. Tykerb (Lapatinib): Side Effects, How it Works, and More

Tykerb (chemical name: lapatinib) is a HER2 inhibitor targeted therapy. Tykerb works against HER2-positive breast cancers by blocking certain ...

#47. Lapatinib - Cancer Australia

Lapatinib (Tykerb®) is a biological therapy for women with HER2-positive metastatic breast cancer. Clinical trials have shown that when ...

#48. KEGG DRUG: Lapatinib ditosylate

Lapatinib tosilate hydrate (JAN); Lapatinib ditosylate monohydrate; Tykerb (TN); Tyverb (TN). Product. TYKERB (Novartis Pharmaceuticals Corporation).

#49. EZH2+inhibitors在lapatinib處理之HER2low/neg乳癌細胞抑制 ...

Herceptin為最早上市之HER2標靶藥物，可有效延長HER2陽性病患之存活率，Lapatinib為新一代之HER2標靶藥物，為EGFR/HER2之酪胺酸激酶抑制劑，能治療以化療合併Hercetin ...

#50. Overnight fasting before lapatinib administration to breast ...

Lapatinib (Tykerb®, GlaxoSmithKline, Brentford United Kingdom) is an oral antihuman epidermal growth factor receptor (HER2) and anti-epidermal ...

#51. Evaluation of the proper dosage of lapatinib and its safety in ...

Lapatinib is a low-molecular-weight agent targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).

#52. lapatinib | Cancer Care Ontario

lapatinib. ( la-PA-ti-nib ). Other Name(s): Tykerb®. Appearance: oval tablet. Drug Formulary information is intended for use by healthcare professionals.

#53. Lapatinib | CancerQuest

Lapatinib · metastaticThe term for a cancer that has spread beyond its point of origin. Metastatic disease is responsible for the majority of cancer deaths.

#54. Lapatinib in patients with metastatic breast cancer following ...

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian ...

#55. Lapatinib: View Uses, Side Effects and Medicines - 1MG

Lapatinib is an anti-cancer medication. This works against the HER2 (human epidermal growth factor receptor protein) receptors and EGFRs ...

#56. Pyrotinib versus lapatinib therapy for HER2 positive metastatic ...

Pyrotinib combined with chemotherapy is superior to lapatinib combined with chemotherapy among HER2+ metastatic breast cancer patients, with a significant ...

#57. Doxorubicin and Lapatinib Combination Nanomedicine for ...

The use of lapatinib as an adjuvant sensitized drug resistant MCF-7/ADR cells to doxorubicin treatment. Cellular uptake studies showed enhanced ...

#58. Drug: Lapatinib - Cancerrxgene

Cell line TCGA classification Tissue Tissue sub‑type IC50 AUC NCI‑H1648 LUAD lung lung_NSCLC_adenocarcinoma 0.031265 0.305249 OCUB‑M BRCA breast breast 0.057212 0.368986 HCC2218 BRCA breast breast 0.067734 0.418857

#59. Lapatinib - SingHealth

​Lapatinib is an oral targeted medication used to treat advanced breast cancer. It is normally given together with another oral medication, ...

#60. Frontiers in Anti-Cancer Drug Discovery

Patients received AC followed by weekly paclitaxel concurrently with trastuzumab, lapatinib, or a combination of trastuzumab plus lapatinib.

#61. Adverse Events and Oncotargeted Kinase Inhibitors

use of proton-pump inhibitors, causing an average of 27% decrease in lapatinib exposure, was issued. In April 2013, interim data from two additional studies ...

#62. Efficacy and safety of lapatinib and trastuzumab for HER2 ...

Objectives The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic ...

#63. Lapatinib & Capecitabine in Advanced Breast Cancer

Lapatinib in combination with capecitabine is recommended as a treatment option for advanced or metastatic breast cancer. National Cancer Drug Fund criteria ...

#64. Role of Lapatinib in HER2-Positive Breast Cancer - OncLive

Lapatinib is approved for use with capecitabine for patients with HER2-positive breast cancer. In some situations, Rugo notes that she utilizes ...

#65. 194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib ...

194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer.

#66. Lapatinib clinical trial update - GSK

In the United States, lapatinib is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor ...

#67. Q-TWiST analysis of lapatinib combined with capecitabine for ...

Abstract. The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women ...

#68. Phase I Study and Biomarker Analysis of Lapatinib and ...

This article describes a phase I dose-escalation study that assessed the toxicity and safety of combining daily lapatinib with radiation therapy for ...

#69. 泰嘉錠膜衣錠 - 台灣癌症資訊全人關懷協會

中文名稱：泰嘉錠膜衣錠英文名稱：Lapatinib Ditosylate藥品：Tykerb藥品分類：標靶治療藥物仿單適應症：在和capecitabine併用的情況下，TYKERB適用於 ...

#70. lapatinib - Healthdirect

More information is available on lapatinib including side effects, age restrictions, food interactions, whether the medicine is available at a government ...

#71. [臨床藥學]口服標靶藥物Lapatinib (Tykerb 泰嘉錠) 用於轉移且 ...

[臨床藥學]口服標靶藥物Lapatinib (Tykerb 泰嘉錠) 用於轉移且對化療無效乳癌病人(Lapatinib in Women with ErbB2-positive, Trastuzumab-Refractory ...

#72. The efficacy of lapatinib and capecitabine in HER-2 positive ...

Lapatinib therapy provided an overall response rate of 30% on BMs in this setting. Abstract. Introduction. Breast cancer (BC) with HER-2/neu ...

#73. Targeted lapatinib anti-HER2/ErbB2 therapy resistance in ...

Lapatinib is a selective, reversible, ATP-competitive tyrosine kinase inhibitor that binds to both HER2 and the epidermal growth factor (EGFR/HER1)[21,27,29 ...

#74. Lapatinib for breast cancer: a review of the current literature

Lapatinib is an oral tyrosine kinase inhibitor which has both HER-1 and -2 activities and has been licensed for use in recurrent breast cancer ...

#75. A trial looking at lapatinib, Herceptin and an aromatase ...

This trial is looking at lapatinib, Herceptin (also known as trastuzumab) and hormone therapy as the first treatment for breast cancer that has spread.

#76. Lapatinib: clinical benefit in patients with HER2-positive ...

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine ...

#77. "Meta-analysis of Lapatinib plus Capecitabine versus ...

To quantify the effectiveness of lapatinib plus capecitabine combination therapy versus capecitabine monotherapy in treating metastatic breast cancer, a ...

#78. Pyrotinib Produces Improved Survival vs Lapatinib in HER2 ...

A combination of pyrotinib plus capecitabine resulted in improved overall survival (OS) compared with lapatinib (Tykerb) plus capecitabine, ...

#79. Adding Adjuvant Lapatinib to Trastuzumab Not Effective for ...

Adjuvant treatment that includes lapatinib did not significantly improve disease-free survival compared with trastuzumab alone.

#80. A randomized phase II trial of trastuzumab plus capecitabine ...

lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes:.

#81. 拉帕替尼_百度百科

拉帕替尼（Lapatinib），是一种化学品。化学名称N-[3-氯-4-[(3-氟苯基)甲氧基]苯基]-6-[5-[(2-甲磺酰乙基氨基)甲基]-2-呋喃基]喹唑啉-4-胺，分子式为C29H26ClFN4O4S， ...

#82. Lapatinib for advanced or metastatic breast cancer.

Lapatinib is a potent reversible and selective inhibitor of the tyrosine kinase domains of epidermal growth factor receptor and human ...

#83. Lapatinib for breast cancer (for use in women with previously ...

Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

#84. Lapanix(Lapatinib) - Beacon Pharmaceuticals PLC

Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase domains of both EGFR (ErbB1) and of HER2 (ErbB2) receptors.

#85. Lapatinib Tablet Ip 250mg Tylidys, Zydus, 30 Tab

TYLIDYS contains Lapatinib which belongs to the group of medicines called antineoplastic agent. It is used to treat HER2-positive breast cancer which have ...

#86. Research and Markets: GSK's Tykerb (lapatinib) HER2 ...

Research and Markets: GSK's Tykerb (lapatinib) HER2-Positive Breast Cancer Treatment Report 2014 - Forecast and Market Analysis to 2023.

#87. Lapatinib - Manfaat, dosis dan efek samping - Alodokter

Lapatinib adalah obat untuk mengobati kanker payudara, terutama yang sudah menyebar atau metastasis. Umumnya, obat ini akan dikombinasikan ...

#88. Lapatinib 250mg Tablet Price: Buy Tykerb, Uses, Dosage

Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It retained significant activity against breast cancer cell ...

#89. Lapatinib - Anwendung, Wirkung, Nebenwirkungen

Lapatinib ist ein Tyrosinkinase-Inhibitor, der die Rezeptor-Tyrosinkinasen EGFR (ErbB1) und HER2 (ErbB2) inhibiert.

#90. Mechanism of action of lapatinib. eRBB2 ... - ResearchGate

Lapatinib is a dual tyrosin kinase inhibitor of EGFR and HER2. It exhibits its anticancer effect via blocking intracellular domain of HER2 receptor in breast ...

#91. LAPATINIB DITOSYLATE MONOHYDRATE的適應症、成分

LAPATINIB DITOSYLATE MONOHYDRATE的成分、用量、副作用，LAPATINIB DITOSYLATE MONOHYDRATE適應症:先前已接受其他藥物治療的晚期或轉移性荷爾蒙陽性乳腺癌患者。

#92. Tykerb Lapatinib 250mg 70 Comprimidos Recubiertos

Principio Activo: Lapatinib / Forma Farmacéutica: Comprimidos / Dosis por Forma ... que se ingieren vía oral, cada comprimido contiene 250mg de Lapatinib.

#93. Lapatinib as first-line treatment for muscle-invasive urothelial...

Naša onkologinja Maša Vilfan bo govorila o uporabi lapatiniba: Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in ...

#94. Lapatinib 250mg 30 Tablets Exporters - Azista Industries

Lapatinib is a small molecule and belongs to a 4-anilinoquinazoline class of Kinase inhibitors. It is the monohydrate of the ditosylate salt.

#95. Lapatinib is a Potent Inhibitor of the ErbB-2 and EGFR ...

Lapatinib is a reversible and specific tyrosine kinases receptor inhibitor of ErbB1 and ErbB2. Besides, it possesses high affinity with ...

#96. 拉帕替尼| 泰立沙| Lapatinib | Tykerb

拉帕替尼| 泰立沙| Lapatinib | Tykerb临床上主要用于联合卡培他滨治疗ErbB-2过度表达的，既往接受过包括蒽环类、紫杉醇、曲妥珠单抗(赫赛汀)治疗的晚期或转移性乳腺癌 ...

#97. TYKERB (lapatinib) tablets - South Delhi Pharma

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine ...